Last reviewed · How we verify
Sublingual administration
At a glance
| Generic name | Sublingual administration |
|---|---|
| Sponsor | Biomind Labs Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sublingual Cannabidiol for Anxiety (PHASE2)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project (NA)
- A Bundled Intervention - Phase 2 (PHASE4)
- Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy (PHASE1, PHASE2)
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual administration CI brief — competitive landscape report
- Sublingual administration updates RSS · CI watch RSS
- Biomind Labs Inc. portfolio CI